Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672695 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03672695 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 37 participants.
The verdict
NCT03672695, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.
Interventions
- COMBINATION_PRODUCT S 64315 (also referred as MIK665) and venetoclax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672695
The ClinicalTrials.gov registry entry for NCT03672695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S 64315 (also referred as MIK665) and venetoclax is the first listed.
NCT03672695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03672695 about?
NCT03672695 is a clinical study titled "Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.". The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.
What is the current status of trial NCT03672695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-11-28. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT03672695?
The interventions under investigation include: S 64315 (also referred as MIK665) and venetoclax (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03672695?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.